AbCellera Biologics

AbCellera’s legacy model captures research fees plus milestones and royalties typically in the low single‑digit range. Notably, the mean royalty rate improved to 4.2 percent for 2020‑2025 deal vintages versus 2.4 percent for 2015‑2019, reflecting better partner terms as capabilities scaled.

However, even at 4.2 percent, royalty leverage requires very large partner sales to translate into material free cash flow, and the path/timing to those sales is inherently uncertain.

The December 2025 Bruker settlement added an upfront (36.0 million dollars recognized in 2025) and created a new, albeit non‑therapeutic, royalty stream, which helps validate IP value but does not solve drug‑economics cyclicality.

Internal programs could confer true pricing power if successful (full product economics), yet those outcomes are several years away.